Previous close | 1.2300 |
Open | 1.2000 |
Bid | 1.2200 x 2900 |
Ask | 1.2500 x 2700 |
Day's range | 1.2000 - 1.2415 |
52-week range | 0.8500 - 2.2400 |
Volume | |
Avg. volume | 9,424,382 |
Market cap | 857.3M |
Beta (5Y monthly) | 1.84 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.